Documents & Downloads

Darlifarnib

Farnesyl Transferase Inhibitor

Darlifarnib is an orally active farnesyl transferase inhibitor that disrupts the mTORC1 signaling pathway. This compound enhances the anti-angiogenic effects of tyrosine kinase inhibitors, making it effective in combination therapies. Darlifarnib is particularly relevant in renal cell carcinoma research, as it promotes tumor regression and inhibits neovascularization when used alongside anti-VEGFR tyrosine kinase inhibitors. Additionally, it sensitizes tumors that have progressed following anti-VEGFR TKI treatment.

Out of Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Specifications

Manufacturer	Adooq Bioscience
Actions	Inhibitor
CAS Number	3065226-39-0
Applications	Farnesyl Transferase Inhibitor
Formula	C₂₉H₂₀N₆O
Molecular Weight	468.51
Synonyms	KO-2806
SMILES	N#CC1=CC(C2=CC(OCC3=CC([C@@]4(C5=CN=CN5C)N)=CC=C3C#N)=CC=C2)=C6C=C4C=CC6=N1

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.